Figure 2.

One-way sensitivity analyses show the lower and upper values for the cost-effectiveness ratio of the Gefitinib strategy to the Control strategy for each parameter.

Zhu et al. BMC Cancer 2013 13:39   doi:10.1186/1471-2407-13-39
Download authors' original image